Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan) (POTTOR)

Viatris

Status: Completed

Conditions: Overactive Bladder

Treatments: Drug: Tolterodine tartrate

Study type: Observational

Funder types: Industry

Identifiers

NCT01488578

A6121186

Details and patient eligibility

About

The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the Package Insert (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in this surveillance, and 3) factors considered to affect the safety and/or efficacy of this drug.

Full description

All the subjects whom an investigator prescribes the first Detrusitol Capsule should be registered consecutively until the number of subjects reaches target number in order to extract patients enrolled into the investigation at random.

Enrollment: 11,157 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Male or female subjects intend to treat their overactive bladder who are prescribed Detrusitol Capsule by their physicians.

Exclusion criteria

• Subjects who have been prescribed Detrusitol Capsule before.

Trial design

11,157 participants in 1 patient group

Tolterodine tartrate.

Description:

Subjects taking Tolterodine tartrate.

Treatment:

Drug: Tolterodine tartrate